Sinogen Pharmaceutical's investigational new drug has been selected for the service list of key drug varieties in the Greater Bay Area

Cell Death and Disease (IF:9.0) published oncological bacterium SalMet-Vac ® research paper on the treatment of osteosarcoma

Guangzhou Sinogen (HuaJin) Pharmaceutical's Oncolytic Bacteria Product SalMet-Vac® Gained FDA Fast Track Designation for the Treatment of HSNCC Patients

May 22, 2024. Guangzhou Sinogen (HuaJin) Pharmaceutical announced that its proprietary bacterial oncolytic product, SalMet-Vec®, has been granted a fast track designation (FTD) by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable recurrent or metastatic head and neck squamous cell carcinoma (HSNCC) who have received at least two prior lines of therapy

Guangzhou Sinogen (Hua Jin) Pharmaceutical Launches Phase II Clinical Trial of the Oncolytic Bacteria Product, SalMet-Vec®, for the Treatment of Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

April 17, 2024. Guangzhou Sinogen Pharmaceutical announced that it has initiated a Phase II clinical trial of the oncolytic bacteria product, SalMet-Vec®, for the treatment of advanced Head and Neck Squamous cell carcinoma (HNSCC) for the patients who have failed standard care therapies (including the second line). West China Hospital of Sichuan University is the lead organization of this clinical trial, and other hospitals will also participate in this Phase II clinical study.

Sinogen Pharmaceutical's oncolytic bacteria product SalMet-Vac® has obtained FDA Fast Track Designation

On January 23, 2024, The oncolytic bacteria injection SalMet-Vec® which is independently developed by Guangzhou Sinogen Pharmaceutical, was granted a fast track designation (FTD) by the US Food and Drug Administration (FDA) for the treatment of metastatic osteosarcoma patients who have received at least two treatments in the past. Obtaining